Delhi High Court Clears Zydus Lifesciences to Sell Anti-Cancer Drug in India

The Delhi High Court on Monday cleared the way for Zydus Lifesciences to manufacture and sell an anti-cancer drug, a biosimilar of an ER Squibb and Sons (better known as Bristol-Myers Squibb), in India. The decision by a division bench of the High Court overturns a single judge’s decision from July 18, 2025, which had restrained Zydus from manufacturing and selling the drug, as an interim measure, in a suit by Bristol-Myers Squibb (BMS) alleging patent infringement by the Indian firm. The relief from the division bench for Zydus comes months before the patent is set to expire on May 2 this year.